Effect of the JAK Inhibitor Baricitinib on Cytokine Production and Bone Properties in a Mouse Model of Accelerated Aging. [PDF]
Gelles K +6 more
europepmc +1 more source
Case Report: Repigmentation and complete hair regrowth in an 11-year-old preadolescent with alopecia totalis treated with a JAK inhibitor. [PDF]
Jia Y, Wang X, Liu Y, Xu Z, Zhang B.
europepmc +1 more source
Effectiveness of Baricitinib in Treating Atopic Dermatitis in Difficult-to-treat Areas: A Retrospective Real-world Study. [PDF]
Lauletta G +5 more
europepmc +1 more source
Body mass index and baricitinib treatment effect in hospitalized adults with COVID-19: A secondary analysis of ACTT-2. [PDF]
Rigsby R, Gaulton TG.
europepmc +1 more source
Non-ST-Segment Elevation Myocardial Infarction (NSTEMI) in a High-Risk Rheumatoid Arthritis Patient on Long-Term Baricitinib: Drug Signal or Risk Factor Convergence? [PDF]
Alghaithi AD, Alnaqbi KA.
europepmc +1 more source
The protective efficacy of baricitinib against lipopolysaccharide / D-Galactosamine-Induced acute liver Injury. [PDF]
Almutairi KK, Hazem SH, Suddek GM.
europepmc +1 more source
Multisite lichen planopilaris, oral lichen planus, and vulvar lichen sclerosus treated using Janus kinase inhibitors. [PDF]
Paz M, Ezzat RZ, Kreytak C, Senna MM.
europepmc +1 more source
IFN-related gene expression defines disease activity, organ involvement and treatment response in JDM. [PDF]
Codes-Méndez H +7 more
europepmc +1 more source
Real-World Use of Baricitinib in Patients with Atopic Dermatitis in Spain: DAMA-S Study, A Retrospective Chart Review. [PDF]
Gómez de la Fuente E +14 more
europepmc +1 more source

